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Background: Cyclin D1 (CCND1) is critical in the transition of the cell cycle from the G1 to S phases, and unbalanced
cell cycle regulation is a hallmark of carcinogenesis. Numerous epidemiological studies have evaluated the association
between the CCND1 A870G polymorphism and the risk of prostate cancer (PCa). However, these studies have yielded
conflicting results.
Methods: In the present study, the possible association above was assessed by a meta-analysis. Eligible articles were
identified for the period up to July 2014. Pooled odds ratios (ORs) with 95% confidence intervals (95% CI)
were appropriately derived from fixed effects or random effects models.
Results: A total of ten case-control studies, which included 3,820 cases and 3,825 controls, were identified.
Overall, the allelic/genotypic association between the G870A polymorphism and prostate cancer was nonsignificant
(OR = 1.045, 95% CI = 0.947 to 1.153 for A versus G, P = 0.380; OR = 1.088, 95% CI = 0.896 to 1.321 for AA versus GG,
P = 0.393; OR = 1.044, 95% CI = 0.941 to 1.158 for GA versus GG, P = 0.414; OR = 1.053, 95% CI = 0.955 to 1.161 for the
dominant model AA + GA versus GG, P = 0.303; OR = 1.072, 95% CI = 0.881 to 1.306 for the recessive model AA versus
AA + GA, P = 0.486). Moreover, subgroup analyses according to ethnicity failed to demonstrate a significant association
between this polymorphism and prostate cancer. In addition, we also performed a stratified analysis of cases with PCa
metastasis, and the results supported the findings of no significant association between CCND1 A870G polymorphism
and metastasis risk of PCa.
Conclusions: Our results suggest that the CCND1 A870G polymorphism might not be a potential candidate for
predicting prostate cancer risk, including metastasis risk.
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As one of the most frequent malignant diseases among
men, prostate cancer (PCa) is a complex disease that is
caused by a multitude of factors [1]. Recently, studies have
revealed that genetic factors play an important role in the
development of sporadic prostate cancer [2,3], which
might provide a potential method for targeted therapy of
PCa. Therefore, there is increasing interest in the role that
genetic variants such as single nucleotide polymorphic
variants (SNPs) play in prostate cancer risk.* Correspondence: urology@zju.edu.cn
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unless otherwise stated.Cell cycle dysregulation plays a critical role in a variety
of malignancies and contributes to an increased risk of
metastasis, in part, by altering the cell’s ability to re-
spond appropriately to DNA damage [4,5]. A number
of studies have linked alleles in these genes to increased
cancer risk or decreased survival in prostate cancer [6-10].
Cyclin D1, also known as CCND1, is localized to the nu-
cleus and plays a key role in the transition from the G1 to
S phase, which promotes the progression of the cell cycle
during cell division [11]. The overexpression of CCND1
has always been observed in numerous types of malignant
cancer and indicates a poor clinical outcome [12-14].
Cyclin D1 mRNA is alternatively spliced to transcribe two
different transcripts, which yield to functionally differentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of study selection based on the inclusion
and exclusion criteria.
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CCND1 is involved, alternatively, in splicing of CCND
mRNA [15].
Epidemiological studies have reported the association
between the CCND1 A/A genotype and the risk of various
cancers. Qin et al. found that the CCND1 A/A genotype
may increase brain tumor risk, especially for gliomas [17].
Yang et al. also reported that an A870G polymorphism in
CCND1 confers an increased risk for breast cancer [18].
However, He et al. revealed that a CCND1 G870A poly-
morphism has no association with esophageal cancer
risk in ethnicity and histology [19]. Although a number
of studies have been performed to assess the association
between the CCND1 A870G polymorphism and prostate
cancer susceptibility, the conclusions have been inconsist-
ent. Wang et al. reported that the A allele of the CCND1
A870G polymorphism was recessively associated with
susceptibility to PCa [10]. But no association between the
CCND1 A870G polymorphism and prostate cancer was
found by Chen et al. [20].
In the present study, ten case-control studies on the
CCND1 A870G polymorphism and prostate cancer risk,
which were previously published, were analyzed via a meta-
analysis to examine a more specific association between
the CCND1 A870G polymorphism and prostate cancer
risk and various published observational studies.
Methods
Literature search
The PubMed, MEDLIN, and Web of Science databases
were searched for studies published before July 2014. The
key words used for searching were as follows: CCND1/
cyclin D1, prostate cancer/carcinoma/tumor, variant/
genotype/polymorphism/SNP, and the combined phrases
for all genetic studies on the association between the
CCND1 A870G polymorphism and prostate cancer risk.
We also checked the references of the retrieved studies
and reviews to ensure the complement of this meta-
analysis. This work was approved by the ethics commit-
tees of Zhejiang Provincial People’s Hospital.
Inclusion criteria
The following inclusion criteria were used for the litera-
ture selection in our meta-analysis: (a) case-control study,
(b) evaluation of the CCND1 polymorphism and prostate
cancer risk, and (c) sufficient published data for both pa-
tients and controls.
Exclusion criteria
The following exclusion criteria were set: (1) incomplete
raw data, (2) repetitive reports (if studies had partly or
completely overlapping data, only the largest or most re-
cent sample was selected), (3) materials and methodswere not well-described and reliable, or (4) not an
English paper.
Data collection
Two investigators extracted information independently
according to the inclusion and exclusion criteria listed.
When it came to conflicting evaluations, an agreement
was reached after a discussion. For each eligible study, we
collected information as follows: the first author’s name,
publication data, country of origin, sources of controls,
number of different genotypes, and ethnicity of the study
population (categorized as Asian and Caucasian). For
studies including subjects of different ethnic groups, data
were extracted separately for each ethnic group whenever
possible.
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) for the control
group of each study was assessed using a goodness-of-fit
test (χ2 of Fisher’s exact test). Heterogeneity and cumu-
lative analysis were assessed by χ2-based Q test. OR esti-
mation was calculated with the fixed effect model
(Mantel-Haenszel method) when statistical heterogeneity
did not exist (P > 0.10). Otherwise, the random effects
model (DerSimonian and Laird method) was selected.
Crude odds ratios (ORs) with 95% confidence intervals
(CIs) were used to assess the strength of association be-
tween the CCND1 polymorphism and prostate cancer
risk. The pooled ORs were performed for a codominant
model (GA versus GG and AA versus GG), dominant
model (GA/AA versus GG), and recessive model (AA ver-
sus GA/GG). Stratified analyses were also performed by
ethnicity. Publication bias was evaluated by Funnel plots,
Table 1 CCND1 A870G genotype distribution and allele frequency in cases and controls
Author and year Ethnicity Method Genotype (N) P HWE
controlsCase Control
GG GA AA GG GA AA
Wang et al. [10] Japanese PCR-RFLP 55 102 57 75 139 40 0.065
Mandal et al. [24] Indians PCR-RFLP 38 65 89 58 93 73 0.013
Comstock et al. [21] African-Americans Taqman 387 258 30 374 246 27 0.086
Comstock et al. [21] Latinos Taqman 212 313 118 214 315 117 0.954
Comstock et al. [21] Japanese Taqman 121 233 103 126 229 112 0.691
Comstock et al. [21] Native Hawaiians Taqman 14 40 17 12 32 24 0.814
Comstock et al. [21] European Americans Taqman 117 242 97 134 225 90 0.800
Comstock et al. [21] Australians Taqman 241 422 166 225 354 160 0.349
Kibel et al. [22] Americans Pyrosequencing 56 88 40 54 100 62 0.285
Koike et al. [23] Japanese PCR-RFLP 22 54 23 21 73 21 0.004
HWE, Hardy-Weinberg equation; PCR-RFLP, Polymerase chain reaction restriction fragment length polymorphism.
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tect publication bias. Statistical analysis was performed




After an extensive search, a total of 43 relevant studies
were identified (Figure 1). Following a careful review,
five published papers with ten case-control studies were
identified, with 3,820 patients with prostate cancer and
3,825 controls [10,21-24]. Table 1 presents the main char-





A versus G 1.045 0.947 to 1.153
Asians 1.100 0.891 to 1.358
Caucasians 1.026 0.911 to 1.157
AA versus GG 1.088 0.896 to 1.321
Asians 1.245 0.766 to 2.024
Caucasians 1.043 0.835 to 1.303
GA versus GG 1.044 0.941 to 1.158
Asians 0.994 0.785 to 1.258
Caucasians 1.056 0.941 to 1.186
GA + AA versus GG 1.053 0.955 to 1.161
Asians 1.046 0.837 to 1.308
Caucasians 1.054 0.945 to 1.176
AA versus GG + GA 1.072 0.881 to 1.306
Asians 1.313 0.793 to 2.174
Caucasians 1.003 0.807 to 1.248the various genotypes of each study in different popula-
tions. A flow diagram schematizing the process of selected
and excluded articles with specific reasons for each is pre-
sented in Figure 1. All studies are case-control studies. Of
these ten studies, three used polymerase chain reaction re-
striction fragment length polymorphism (PCR-RFLP), six
used 5′-nuclease Taqman allelic discrimination assay, and
one used pyrosequencing. The studies were carried out in
Japan, UK, Australia, and India. Three studies were on
Asians and seven studies were on Caucasians. The studies
carried out with Japanese were used in the Asian sub-
group, and others were used in Caucasian subgroup. The
distribution of genotypes in the controls was consistentA870G polymorphism and prostate cancer risk
P value Heterogeneity Effects
modelI2 (%) P value
0.380 49.7 0.037 Random
0.374 48.8 0.142
0.669 55.8 0.035
0.393 43.0 0.071 Random
0.376 57.1 0.096
0.711 43.1 0.104
0.414 0.0 0.936 Fixed
0.958 0.0 0.577
0.350 0.0 0.891
0.303 0.0 0.696 Fixed
0.690 0.0 0.538
0.341 0.0 0.520
0.486 59.8 0.008 Random
0.290 72.6 0.026
0.976 56.3 0.033
Figure 2 Forest plots of the CCND1 A870G polymorphism in prostate cancer versus control and subgroup analyses. The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond
represents the summary OR and 95% CI. CI, confidence interval; OR, odds ratio.
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except for Mandal et al. (P = 0.013) and Koike et al.
(P = 0.004).
Quantitative data synthesis
Table 2 shows the results on the association between the
CCND1 A870G polymorphism and prostate cancer risk.
The combined results based on all studies revealed that
variant genotypes are not associated with increased
prostate cancer risk in different genetic models (OR =
1.045, 95% CI = 0.947 to 1.153 for A versus G, P = 0.380;
OR = 1.088, 95% CI = 0.896 to 1.321 for AA versus GG,
P = 0.393; OR = 1.044, 95% CI = 0.941 to 1.158 for GA
versus GG, P = 0.414; OR = 1.053, 95% CI = 0.955 to 1.161
for the dominant model AA+GA versus GG, P = 0.303;
OR = 1.072, 95% CI = 0.881 to 1.306 for the recessive






AA versus GG 1.072 0.645 to 1.782
GA versus GG 0.842 0.513 to 1.382
GA + AA versus GG 0.933 0.595 to 1.462
AA versus GG + GA 1.230 0.824 to 1.837We also performed subgroup analyses by ethnicity,
and the results are listed in Table 2. The results revealed
no significant associations between the CCND1 A870G
polymorphism and prostate cancer in genotype distribu-
tions in Asians and Caucasians.
In our present study, we also performed a stratified ana-
lysis of cases with PCa metastasis, and the results revealed
no significant association between the CCND1 A870G
polymorphism and metastasis risk of PCa (Table 3).
Heterogeneity analysis
The following genetic model of the ten studies showed
statistically significant heterogeneity using the Q statistic
(A versus G: I2 = 49.7%, P = 0.037; AA versus GG: I2 =
43.0%, P = 0.071; AA versus GG +GA: I2 = 59.8%, P =
0.008), and the random effects model was employed in
these studies. We did not find significant heterogeneityA870G polymorphism and metastasis risk of prostate
P value Heterogeneity Effects
modelI2 (%) P value
0.788 63.3 0.066 Random
0.496 31.2 0.234 Fixed
0.762 48.4 0.144 Fixed
0.312 53.6 0.116 Fixed
Table 4 Publication bias test for the CCND1 A870G polymorphism
Comparisons Egger’s test Begg’s test P value
Coefficient P value 95% CI
A versus G 0.191 0.889 −3.171 to 3.554 0.721
AA versus GG 0.156 0.909 −2.899 to 3.210 1.000
GA versus GG −0.640 0.249 −1.829 to 0.548 0.371
AA + GA versus GG −0.329 0.674 −2.067 to 1.409 0.721
AA versus GG + GA 0.709 0.678 −3.083 to 4.500 0.721
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0.936; AA +GA versus GG: I2 = 0.0%, P = 0.696), and a fixed
effects model was performed.
Publication bias
A Funnel plot and Egger’s test were performed to estimate
the publication bias of the literature. The Egger-weighted
regression method suggested that there was no evidence
of publication bias for the CCND1 G720A polymorphism
(P = 0.889 for A versus G, P = 0.909, for AA versus GG,
P = 0.249 for GA versus GG, P = 0.674 for AA +GA versus
GG, P = 0.678 for AA versus GG+GA). This result was
confirmed by the Begg’s rank correlation method (P = 0.721
for A versus G, P = 1.000 for AA versus GG, P = 0.371 for
GA versus GG, and P = 0.721 for AA +GA versus GG, P =
0.721 for AA versus GG+GA) (Table 4, Figure 3).
Discussion
Cell cycle regulation plays an important role in the
evolution of cancer by influencing cell proliferation,Figure 3 Funnel plot was used to detect the publication bias for diffedifferentiation, and apoptosis [25]. CCND1, a key regula-
tory protein, plays an important role in the transition from
the G1 to S phase of the cell cycle [15], and its deregula-
tion has been implicated in the pathogenesis of several
types of cancers [26,27]. Many polymorphisms have been
identified in CCND1. A common functional polymorph-
ism, G870A (rs603965), which increased the frequency of
alternative splicing and encoded a protein with an al-
tered C-terminal domain and increased the stability or
half-life of the protein, has garnered wide attention. To
date, several studies have reported the role of the CCND1
G870A polymorphism in prostate cancer risk [10,22,24].
But the results are controversial, partially because of the
possible small effect of the polymorphism on PCa cancer
risk. In order to estimate the overall risk of the CCND1
G870A polymorphism associated with prostate cancer, we
conducted a meta-analysis of results from ten case-control
studies on the association of the CCND1 G870A poly-
morphism with PCa risk. Overall, a total of 3,820 cases
and 3,825 controls were included. However, the resultsrent genetic models. Each point represents a separate study.
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A870G polymorphism and PCa risk was found.
Wang et al. [10] showed that the CCND1 A allele was
more frequently observed in the PCa group than the con-
trol group, and men with the AA genotype had an increased
risk of PCa compared to those with the GG genotype.
Mandal et al. [24] also revealed that the CCND1 AA
genotype was observed to be associated with a significant
increase in PCa risk. However, Koike et al. found that no
significant association of the genotype frequency of the
CCND1 with overall cases and controls [22]. Our present
study showed that no significant association between the
CCND1 A870G polymorphism and PCa risk was found.
Stratification analysis showed that the CCND1 A allele
showed significantly increased risk of PCa metastasis
[23]. But Mandal et al. did not find any significant risk
when analyzing data for the risk of susceptibility for me-
tastasis with the CCND1 polymorphism [24]. In our
present study, we also performed a stratified analysis of
cases with PCa metastasis, and the results supported the
findings that there is no significant association between
CCND1 A870G polymorphism and metastasis risk of PCa,
as reported by Mandal et al. [24]. But the findings were in-
consistent with Koike et al. [23]. Base on the previous
studies, the reasons for the discrepancy between our study
and previous studies may be various. Genetic heterogen-
eity is an inevitable problem in any disease identification
strategy [28]. Different genetic backgrounds may cause
this discrepancy, or different populations may have differ-
ent linkage disequilibrium patterns. So, we hypothesized
that the CCND1 A870G polymorphism might be in close
linkage with different nearby causal variants in one ethnic
population but not in another, according to the report
of Yu et al. [29]. In addition, a relatively small sample
size, the genotyping method, and the prostate cancer type
were also identified as potentially significant sources of
between-study heterogeneity.
However, some limitations of this meta-analysis should
be addressed. First, the results were based on the un-
adjusted estimates with original data from these collected
studies being unavailable, which limited the evaluation
with certain covariates, including cancer type, smoking,
drinking, age, and other environmental factors. Second,
the controls of several studies were various in the analysis,
which may have induced the bias of the results and pre-
vented the drawing of more detailed conclusions. Third,
the single-locus-based nature of this meta-analysis pre-
cluded the possibility of gene-gene and gene-environment
interactions; the analysis did not consider these factors be-
cause of the lack of sufficient data. Furthermore, we only
concentrated on the CCND1 A870G polymorphism and
did not evaluate other genes or polymorphisms; whether
this polymorphism integrated with other risk factors to
enhance the predictive power requires further study.Conclusions
In conclusion, we expanded previous individually under-
powered studies and suggested that no obvious association
was found between the CCND1 A870G and prostate can-
cer susceptibility. In addition, our observations raise the
question of a potential heterogeneous effect of A870G
across different ethnic populations. Nevertheless, for prac-
tical reasons, we hope that additional studies of CCND1
that include functional DNA repair gene polymorphisms
in a large cohort of different ethnicities, combined with
more appropriate methods, will augment the etiology of
the pathogenesis of PCa.
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